

Alberta Immunization Program Introductions and Changes

Revision Date: April, 2018

Section	Updates	Date
Biological products MMR: Measles Mumps Rubella Combined Vaccine	Updated rubella vaccine indications to include: adults born before 1957 generally presumed to have immunity to rubella.	April 2018
Biological products Varicella: Varicella Vaccine	Updated to include NACI recommendations for varicella proof of immunity: verbal history is not a reliable indicator of immunity in populations where varicella vaccine has been introduced. This recommendation will be phased in starting with the following four groups: children 12 months up to and including 6 years of age, women identified through routine prenatal screening, health care workers (HCW) upon hire, and post-secondary HCW students as they present for immunization.	April 2018
Biological products Rotavirus: Rotavirus Vaccine	Updated to include RotaTeq® which will be used for infants initiating a rotavirus vaccine starting May 1, 2018. RotaTeq® series is three-doses where as Rotarix® is two-doses.	April 2018
Biological products HPV: Human Papillomavirus Vaccine	Updated to incorporate two-dose scheduling for individuals 9 to 14 years of age who are immunocompetent. Implementation is September 2018 for school immunization program.	April 2018
Biological products DTaP-IPV-Hib-HB: Infanrix hexa®	Expand indications to include hepatitis B vaccine as Universal Infant Hepatitis B program for infants born March 1, 2018 or after.	November 2017
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	Incorporated updated CIG guidelines for individuals at high risk: recommend a documented series for those with only verbal history who are anti-HBs positive and recommend a complete second series if anti-HBs negative after first series.	November 2017
Biological products HPV: HPV 9	Expanded eligibility to include MSM 17 to 26 years of age as per NACI recommendation.	October 2017
Biological products Immune Globulin: Immune Globulin (Human)	Updated to incorporate change in dose recommended in Hepatitis A post-exposure as per Grifols Therapeutics Inc. change in prescribing Information and MMWR.	November 2017
Biological products Td/TdP: Tetanus Post-exposure Prophylaxis in Injury/Wound Management	Incorporated management of tetanus-prone wounds for infants younger than 6 months of age who have not received a full three dose primary series of tetanus toxoid-containing vaccine.	September 2017
Biological products dTap vaccine	Included recommendations for immunization of contacts of diphtheria cases and carriers of diphtheria.	September 2017
Biological products Influenza Vaccine: ▪ FLUZONE® ▪ FLUAD®	Influenza Vaccines - Updated for 2017-2018 Influenza season.	July 2017

Section	Updates	Date
Introduction Immunization Goals and Objectives	Rotavirus added - by 12 months of age 80% of children will have received two doses of rotavirus vaccine.	June 2017
Cold chain management AVCC Policy	Alberta Vaccine Cold Chain Policy updated.	March 2017
Adverse event following immunization policy and procedures Adverse Events Following Immunization Policy for Alberta Immunization Providers	Adverse Events Following Immunization Policy for Alberta Immunization Providers updated.	December 2016
Biological Products Polio Vaccine: • Polio: IMOVAX®	<p>Routine Adults - Due to the limited supply of polio vaccine and the low risk of exposure to polio in Alberta and Canada – the recommendation for the routine immunization of unimmunized adults is suspended until further notice.</p> <p>Health Care Workers - Primary series and single life time reinforcement for HCWs who may be exposed to patients excreting polio.</p> <p>Travelers to 'Polio Emergency Countries' - Exporting and/or infected with polio and staying 4 weeks or longer. Primary series and reinforcing dose for adults. http://polioeradication.org/polio-today/polio-now/public-health-emergency-status/</p>	November 16, 2016
Biological Products Td Polio: • Td POLIO ADSORBED	Updated to reflect changes to Polio indications.	November 16, 2016
Biological Products Rabies Vaccine: • IMOVAX® • RabAvert®	<p>Recommendations included for Post-exposure series initiated in another country:</p> <ul style="list-style-type: none"> • If the post-exposure series initiated meets the World Health Organization (WHO) approved vaccine, was administered I.M., and meets WHO approved schedule - complete the series as appropriate. RIG can be offered if the client has not already received RIG and it can be administered within seven days of the first dose of I.M. rabies vaccine. • For uncertain vaccines, vaccines given I.D., or unknown schedule, including no clear documentation - restart series and offer RIG. 	November 16, 2016
Biological products DTaP-IPV-HIB: ▪ INFANRIX®-IPV/Hib ▪ PEDIACEL®	<p>PEDIACEL® revised to include off-license use of infants 6 weeks of age and older.</p> <p>Both PEDIACEL® and INFANRIX-IPV/Hib® updated to reflect current off license use of vaccine for HSCT clients including adults.</p>	September 21, 2016

Section	Updates	Date
Biological products Influenza Vaccine: <ul style="list-style-type: none"> ▪ FLUZONE® ▪ FLUAD® ▪ FLUMIST® 	Influenza Vaccines - Updated for 2016-2017 Influenza season. FLUMIST® <ul style="list-style-type: none"> ▪ Removed preferential recommendation for 2 to 17 years of age. 	August 29, 2016
Biological products Hepatitis B Vaccine: <ul style="list-style-type: none"> ▪ ENGERIX®-B ▪ RECOMBIVAX HB® 	Incorporated updated recommendations from CIG and ACIP for immune compromised individuals and those with renal disease. <ul style="list-style-type: none"> ▪ Recommendation that these individuals who are antiHBs negative after first series receive a second series followed by serology one month later. Included schedule for infants born to HBsAg negative mothers weighing less than 2000 grams who received Hepatitis B vaccine at birth. <ul style="list-style-type: none"> ▪ Neonates weighing less than 2,000 grams who received their first dose of hepatitis B vaccine at birth should receive three additional doses of vaccine administered at 1, 2, and 6 months of age. 	August 25, 2016
Biological products Hepatitis B Immune Globulin (HBIG)	Updated to be consistent with CIG, Red Book and ND guidelines for indications for HBIG. <ul style="list-style-type: none"> ▪ Removed under indications for HBIG: Infants younger than 12 months of age whose primary caregiver is infected with hepatitis B. ▪ Note: this does not include infants born to hepatitis B infected mothers. The indication for HBIG remains. 	August 25, 2016

Section	Updates	Start Date	End Date
Biological products Influenza Vaccine: <ul style="list-style-type: none"> ▪ FLUZONE® ▪ FLUAD® ▪ FLUMIST® 	Influenza Vaccines - Updated for 2016-2017 Influenza season. FLUMIST® e. <ul style="list-style-type: none"> ▪ Removed preferential recommendation for 2 to 17 years of age. ▪ Removed egg-allergic individuals as a contraindication. 	August 29, 2016	
Biological products Hepatitis B Vaccine: <ul style="list-style-type: none"> ▪ ENGERIX®-B ▪ RECOMBIVAX HB® 	Incorporated updated recommendations from CIG and ACIP for immune compromised individuals and those with renal disease. <ul style="list-style-type: none"> ▪ Recommendation that these individuals who are antiHBs negative after first series receive a second series followed by serology one month later. Included schedule for infants born to HBsAg negative mothers weighing less than 2000 grams who received Hepatitis B vaccine at birth. <ul style="list-style-type: none"> ▪ Neonates weighing less than 2,000 grams who received their first dose of hepatitis B vaccine at birth should receive three additional doses of vaccine administered at 1, 2, and 6 months of age. 	August 25, 2016	
Biological products Hepatitis B Immune Globulin (HBIG)	Updated to be consistent with CIG, Red Book and ND guidelines for indications for HBIG. <ul style="list-style-type: none"> ▪ Removed under indications for HBIG: Infants younger than 12 months of age whose primary caregiver is infected with hepatitis B. ▪ Note: this does not include infants born to hepatitis B infected mothers. The indication for HBIG remains. 	August 25, 2016	

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
2016-06-30	Immunization for Adult Solid Organ Transplant Candidates and Recipients. Updated to include detail of evidence of measles immunity.	
2016-06-30	Immunization for Children Expecting Solid Organ Transplant before 18 month of age. Updated to include Rotavirus vaccine.	
2016-06-30	Hepatitis A vaccines – HAVRIX® and VAQTA®. Updated indications to include infants 6 months and older eligible for hepatitis A vaccine.	
2016-04-26	INFANRIX hexa® (Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio- <i>Haemophilus influenza</i> type b Conjugate Combined Vaccine)- new vaccine chart. Indicated for children under 2 years of age eligible for DTaP-IPV-Hib and Hepatitis B.	
2016-04-22	GARDASIL®9 - Implementation of HPV 9 for school program starting 2016-September-01.	
2016-04-13	Polio Vaccine - Indications updated to be in line with CATMAT. Use of provincially funded vaccine for adults traveling to countries where polio is circulating as per WHO Polio Emergency.	
2016-04-13	Td POLIO - Indications updated to be in line with CATMAT. Use of provincially funded vaccine for adults traveling to countries where polio is circulating as per WHO Polio Emergency.	
2015-09-23	FLUZONE®Quadrivalent Indications for use of provincially funded vaccine: included indications for pregnant women.	
2015-08-18	Influenza Vaccines: Influenza charts amended to 2015-2016 season INFLUVAC® - Indications for use of provincially funded vaccine: Removed statement: <i>This is the vaccine of choice for adults 18 to 64 years of age</i>	
2015-08-12	Influenza Vaccines: FLUAD® - Influenza strains for 2015-2016: Indications for use of provincially funded vaccine: Now available to all Albertans aged 65 years and older. FLUMIST®Quadrivalent - Influenza strains for 2015-2016: Precautions: LAIV administration with other live vaccines. Separated Infants & children with sickle cell anemia from adults with sickle cell anemia. FLUVIRAL® - Influenza strains for 2015-2016: Indications for use of provincially funded vaccine: Added children and adolescents with neurologic or neurodevelopment conditions. FLUZONE®Quadrivalent - New vaccine for 2015-2016 seasonal influenza INFLUVAC® - New vaccine for 2015-2016 seasonal influenza	

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
2015-08-12	<p>PNEUMOVAX®23 - Indications for use of provincially funded vaccine: Potential dose change for individuals ≥65 years of age.</p> <p>Schedule: Reinforcing dose changes for children (standardized with the spacing for adults)</p>	
2015-07-24	<p>IMOVAX® Polio - clarification on indications for use of provincially funded vaccine</p>	
2015-07-24	<p>Td Polio Adsorbed - clarification on indications for use of provincially funded vaccine</p>	
2015-06-01	<p>Immunization for Individuals with Inadequate Immunization Records. New document formerly part of Contraindications and Special Situations for immunization. Rewording in general Guidelines and Serologic Testing sections. Internationally adopted children section is new</p>	
2015-06-01	<p>Immunization of Specific Populations. Immunocompromised: general information – rewording, general principles update to CIG statements, Table 1 Vaccines for Immunocompromised individuals and other Chronic Health Conditions is new, information on Immunocompromising conditions contains both reworded sections and new information.</p>	
2015-06-01	<p>Vaccine Codes (Imm/Ari) Appendix 12 New vaccine codes added for Meningococcal B and rotavirus vaccines</p> <p>History of Biologicals Administered in AB Appendix 4.1 Updated</p> <p>History of Alberta Immunization Program Introductions Appendix 4.2 - new document</p>	
2015-02-25	<p>Rabies Imovax/RabAvert – schedule pre-exposure reinforcing doses</p>	
2015-02-25	<p>Meningococcal BEXSERO® - Indications: pre-exposure for specified high-risk individuals and outbreaks and pre-exposure schedules depending on age</p>	
2015-02-25	<p>Contraindications and Precautions - New format and Special Situations for Immunization removed from this document and information reorganized. Wording changes for consistency with CIG Evergreen ed</p> <p>Allergies: hypersensitivity to egg and egg-related antigens – MMR wording change, new sections added for Inactivated Trivalent Influenza vaccine and live attenuated influenza vaccine</p> <p>Biological Products: Live vaccines - new information re live parenteral vaccines, live attenuated influenza vaccines and live oral vaccines</p> <p>New sections: asthma, Guillain-Barré Syndrome, Immunocompromised individuals, Intussusception or congenital malformation of gastrointestinal tract, medications</p>	

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
2015-02-25	Access for Biological Products After Hours - formerly Management of Biologicals - most of information removed leaving only information about access after hours for biological products	
2015-02-10	<p>General Principles for Transplant Recipients Appendix 7, HSCT and SOT guidelines updated.</p> <p>DTaP-IPV/Hib: information added re delay of TAT if on IVIG</p> <p>Meningococcal (children younger than 12 years of age): MenC-ACYW recommended for children younger than 12 years of age - children younger than 2 years to receive Menveo™.</p> <p>HIV infection added to high risk due to underlying medical conditions.</p> <p>Hepatitis B: information regarding delay of serology if on IVIG.</p> <p>MMR: Information added re serology results for indeterminate and negative.</p> <p>Varicella: Point 1 - sentence added re maintenance chemotherapy, point re previous shingles or chickenpox.</p>	
2015-02-10	Hepatitis B Risk Assessment for Paid Workers/Volunteers/Students Appendix 15 - new addition to the manual.	
2015-02-10	Polio Vaccine IMOVAX® Polio – updated. Indications: adults – new recommendations for adults not fully immunized with polio vaccine and at increased risk of exposure to poliovirus. Incorporates recommendations from letter sent by OCMOH August 7, 2014. Possible adverse events following immunization: information about post-marketing surveillance is new.	
2015-02-10	Td Polio Adsorbed - new vaccine chart.	
2015-02-10	Act-Hib®/HIBERIX® - Indications: Individuals 5 years and older regardless of previous Hib immunization with specified chronic conditions. New chronic conditions (malignant hematologic disorders and acquired complement deficiency) added. SOT candidates and recipients expanded to include all SOT not just lung transplantation.	
2015-02-10	TYPHIM Vi® - New vaccine chart	
2015-02-10	Pevnar® 13/ Pneumovax® 23 - Indications: Note added under indication for immunosuppressive therapy regarding medication Soliris®.	
2015-02-10	Menatra®/Menveo™ - Indications: Note re medication Soliris® added under Acquired complement deficiency.	
2015-01-26	FLUMIST® Quadrivalent and Trivalent 2014-2015 - Precautions: 3 rd point re sickle cell anemia is new.	
2015-01-26	M-M-R® II/ PRIORIX® - Indications: First note under Children is new re infants 6 -12 months travelling. Adults: first point under measles regarding Adults born prior to 1970 who are travelling is new. Mumps serology has been removed as marker for mumps immunity.	

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
2015-01-26	PRIORIX-TETRA®/ProQuad™ - Indications: SOT 9 months -12 years of age added to PRIORIX-TETRA® and Note added to ProQuad™ re use of PRIORIX-TETRA® for SOT infants younger than 12 months of age.	
2015-01-02	Menveo™ to be used for high risk children 2 months to 23 months of age.	
2015-01-02	Routine meningococcal conjugate C schedule change to 2 doses (4 and 12 months of age).	
2015-01-02	Hepatitis B indications to include: Individuals with congenital immunodeficiencies, individuals infected with HIV and susceptible adults who have immigrated to Canada from areas where there is a high prevalence of hepatitis B.	
2014-10	Pneumovax® 23 – Illicit drug use added to indications.	
2014-10	<p>Prevnar® Expanded indications for high-risk populations 5 – 18 years of age including: chronic cardiac disease, chronic cerebral spinal fluid (CSF) leak, chronic liver disease (including hepatitis B and C and hepatic cirrhosis due to any cause), chronic neurologic condition that may impair clearance of oral secretions, chronic pulmonary disease (excluding asthma unless treated with high-dose oral corticosteroid therapy), chronic renal disease, including nephrotic syndrome, cochlear implants (candidates and recipients), congenital immunodeficiencies diabetes mellitus (poorly controlled), immunosuppressive therapy and malignant neoplasms (leukemia, lymphoma).</p> <p>Expanded indications for high-risk adult populations added including: asplenia (anatomical or functional), chronic CSF leak, cochlear implants (candidates and recipients), congenital immunodeficiencies, immunosuppressive therapy, malignant neoplasms including leukemia and lymphoma, sickle cell disease and other hemoglobinopathies.</p>	
2014-09-23	BEXSERO® for contacts of meningococcal B.	
2014-10	FLUAD® for Albertans 65 years of age and older living in continuing care facilities such as long term care or supportive living accommodations (such as Daily Assisted Living {DAL}, Seniors Lodges, AHS Home Care Program) and those living in congregate living settings who share common eating areas.	
2014-09-01	Human Papillomavirus Vaccine (GARDASIL®) to include all students (girls and boys) in Grade 5.	
2014-09-01	Human Papillomavirus vaccine (GARDASIL®) four year catch-up for Grade 9 boys.	2018-06-30
2014-03-25	Diphtheria/Tetanus/Acellular Pertussis (dTap) one-time adult booster dose replacing Td if have not already received a dose of dTap in adulthood.	
2014-01-10	Hepatitis A and hepatitis B combined vaccine (TWINRIX®) introduced for adults requiring both hepatitis A and B vaccines.	
2013-09-26	Two life-time doses of measles-containing vaccine recommended for all adults born in 1970 or later and all health care workers regardless of birth year.	

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
2013-09-26	Two life-time doses of mumps-containing vaccine recommended for all health care workers regardless of year of birth.	
2013-08-29	Rabies PEP four doses of vaccine instead of five doses of vaccine for unimmunized, immune competent individuals.	
2012-10	FLUMIST® vaccine for children 2 – 17 years of age.	
2012-09-11	Diphtheria/Tetanus/Acellular Pertussis/IPV (dTAp-IPV) routine booster for 4 – 6 year olds replacing DTaP-IPV.	
2012-08-01	Measles/Mumps/Rubella/Varicella (PRIORIX-TETRA®) second dose introduced for 4 – 6 year olds (i.e. children born August 1, 2005).	
2012-01-01	Diphtheria/Tetanus/Acellular Pertussis (ADACEL® or BOOSTRIX®) one-time adult booster dose replacing Td (not needed if dTap at age 12 years or older)	
2012-01-26	Meningococcal conjugate (groups A, C, Y, W-135) vaccine for individuals at high-risk 56 years and older.	
2011-10	FLUMIST® pilot/research project using 2,000 doses.	2012-03
2011-08	RECOMBIVAX HB® change in dosage for all individuals 0 – 10 years of age from 0.25 mL to 0.5 mL including students in Grade 5.	
2011-02	Meningococcal Conjugate (Groups A, C, Y, W-135) routine Grade 9 program.	
2010-07-01	Pneumococcal vaccine 7-valent conjugate: Pneumococcal Vaccine, 13-valent Conjugate (PREVNAR® 13) replaced 7 valent vaccine for infant program using three dose series (2, 4 and 12 months) instead of previous four dose series (2, 4, 6, and 18 months).	2010-07-01
2010-09-01	Measles/Mumps/Rubella/Varicella (PRIORIX-TETRA®) routine program replacing MMR at 12 months of age.	
2009-12-01	Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant) – pregnant women and individuals 10 to 64 years without immune compromising conditions specifically requesting vaccine without adjuvant.	2010-10-31
2009-10	Influenza seasonal vaccine universal program to include all Albertans six months of age and older.	
2009-10	Influenza vaccine for H1N1 Pandemic universal program for everyone six months of age and older.	2010-10
2009-09-01	Human Papillomavirus types 6, 11, 16 & 18 vaccine (GARDASIL®) four year catch-up for Grade 9 girls.	2013-06-30
2009-02-23	One life-time dose of dTap vaccine recommended for individuals 65 years of age and older when presenting for Td booster.	

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
2008-10	Influenza vaccine recommended for healthy children 24 – 59 months of age and healthy adults 50 – 64 years of age.	
2008-09-01	Human Papillomavirus types 6, 11, 16 & 18 vaccine (GARDASIL®) for Grade 5 girls.	2016-08-31
2008-02-14	Mumps-containing vaccine two doses for health care workers and post-secondary education students born in 1970 or later.	
2007-11	Measles/Mumps/Rubella (second dose for HCW and post-secondary students)	
2007-02-01	Meningococcal Conjugate Polysaccharide (A, C, Y, W-135) for high-risk groups 2 – 55 years of age.	
2005-01	Smallpox (vaccinia) for select laboratory workers.	
2004-09-01	Diphtheria/Tetanus/Acellular Pertussis (dTap) replaced Td as routine Grade 9 booster.	
2003-04	Varicella Zoster vaccine for all susceptible individuals (VARIVAX II & III).	
2002-09-01	Pneumococcal Conjugate 7 Valent Vaccine (PREVNAR®) routine infant program using four dose series (2, 4, 6 and 18 months).	2010-06-30
2002-04-04	Meningococcal conjugate monovalent C vaccine infant program for infants born on or after 2001-09-01.	
2001-07-01	Varicella Zoster Vaccine (VARIVAX® II and III) routine program for children 12 months of age (phased in approach).	
2001-11-01	Meningococcal Conjugate monovalent C (Campaign: 2 – 24 months of age)	2002-03-31
2001-04-01	Varicella Zoster Vaccine (VARIVAX® II and III) for susceptible students in Grade 5 (phased in approach).	2007-06-30
2001-02-06	Meningococcal Polysaccharide Bivalent A, C (Campaign for 2 – 24 years of age).	2002-03-01
2000-02-15	Meningococcal Polysaccharide (quadrivalent A, C, Y, W-135) - Campaign	2000-10-24
1999-09	Hepatitis B catch-up for Grade 12 students.	2002-06
1998-Fall	Pneumococcal Polysaccharide Vaccine for 65 years of age and older.	
1997-04	Pneumococcal Polysaccharide for high-risk groups except 65 years of age and older.	
1997-04-01	Measles (Red) second dose measles catch-up for Grades 1 – 9.	1998-06-30

Start Date (Y-M-D)	Biological and Program Description	End Date (Y-M-D)
1997-01-01	Measles/Rubella second dose measles catch-up for Grades 1 – 9.	1997-12-31
1996-06	Measles/Mumps/Rubella routine program second dose for 4 – 6 year olds.	2010-08-31
1995-09	Hepatitis B Vaccine routine school program for Grade 5 students.	
1992 (approx.)	Influenza vaccine split virus Influenza split virus vaccine first used in Canada in approximately 1992 FLUVIRAL® & VAXIGRIP®)	
1994	<i>Haemophilus influenzae</i> type b (PRPT) routine 2 month schedule	
1988	<i>Haemophilus influenzae</i> type b (PRPD) for 18 months olds	1993
1987	<i>Haemophilus influenzae</i> type b (PRP) for 2 to 3 year olds	1988
1983-09-01	Measles/Mumps/Rubella catch-up program for Grade 1 and Grade 6.	1986
1983-05-04	Meningococcal polysaccharide quadrivalent A, C, Y, W-135 vaccine (MENOMUNE®) for high-risk groups.	2012-01-18
1983-01	Hepatitis B vaccine for high risk infants younger than one year of age.	
1982	Measles/Mumps/Rubella routine program at 12 months of age.	2012-07-31
1972-01-01	Rubella (school program for Grade 6 girls)	1982-01-01
1969-01-01	E/Z Measles (Edmonston-Zagreb, Live)	1971-01-01
1966	Killed measles vaccine introduced	1970-07
1954	Polio Inactivated (Salk) - vaccine trials: pre-licensure	Unknown
1870-01-01	Smallpox (vaccinia) - universal	1980-04-10

For additional information, please contact the manufacturer of the product and/or Health Canada.

References

- ¹ Alberta Health. (2016, February). *Immunization Data Submission and Response Guidelines, Version 5.8*. <http://www.health.alberta.ca/documents/Immunization-Data-Submission-Guidelines-2016.pdf>
- ² Alberta Health and Wellness, Disease Control and Prevention. (2004, May). *Alberta's Meningococcal Immunization Program: A full report*. www.health.alberta.ca/documents/Meningococcal-Campaign-2001.pdf
- ³ AHS (former Calgary Health Region), Communicable Disease Control. (2005, November). *Dates when new programs, vaccines, etc. adopted by Calgary Health Region*.
- ⁴ AHS (former Capital Health Region), Public Health Division, Communicable Disease Control. (2002, December). Biologicals introduced in Alberta. In *Communicable Disease Control Manual* (Appendix 4).
- ⁵ Waters, John. (1996). *Biologicals introduced in Alberta*. Unpublished personal file.